{"nctId":"NCT00852592","briefTitle":"Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial","startDateStruct":{"date":"2009-05"},"conditions":["Bipolar Disorder","Major Depressive Episode"],"count":46,"armGroups":[{"label":"Active Comparator","type":"ACTIVE_COMPARATOR","interventionNames":["Device: 7000lux broad-spectrum light"]},{"label":"Inactive Comparator","type":"PLACEBO_COMPARATOR","interventionNames":["Device: 50lux dim red light"]}],"interventions":[{"name":"7000lux broad-spectrum light","otherNames":[]},{"name":"50lux dim red light","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 18-65 years\n* DSM-IV Criteria BD I or II depressive episode,\n* SIGH-ADS \\>20; duration \\>2 weeks.\n* Stable dose antidepressant drug \\>8 weeks with concurrent antimanic drug\n* Controlled thyroid disease\n* Subjects with preexisting eye diseases will be included.\n* Able to provide informed consent\n* Stable minimum dose antimanic drug \\>4weeks: lithium 0.5 mEq/L, divalproex Na 50 mcg/mL, olanzapine 5mg daily, carbamazepine 4mg/L; lamotrigine 100mg daily, risperidone 2mg daily, quetiapine 400 mg daily, ziprasidone 10 mg bid, and aripiprazole 5 mg qd.\n* Stable unchanged psychotherapy for \\>16weeks\n\nExclusion Criteria:\n\n* The following eye diseases: retinal disease, cataract surgery and lens removal, macular degeneration,\n* Taking photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum.\n* Acute psychosis (DSM-IV Criteria)\n* Rapid cycling in the past 1 year\n* Obsessive compulsive disorder\n* Alcohol or substance abuse or dependence in the past 6 months.\n* MRS\\>5\n* Recent history of a suicide attempt (3 months) or active suicidal Ideation (SIGHADS item H11 \\>2)\n* Beta-adrenergic blockers, exogenous melatonin, chronic NSAIDS","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SIGH-ADS Depression Score","description":"The Structured Interview Guide for the Hamilton Depression Rating Scale-HRS-D with Atypical Depression Supplement (SIGH-ADS) provides a benchmark for depression severity; SIGH-ADS scores range from 0-79; higher values represent increased depression severity and worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"8.18"},{"groupId":"OG001","value":"17.3","spread":"9.53"}]}]}]},{"type":"SECONDARY","title":"Global Assessment of Functioning (GAF)","description":"The GAF is used to assess global psychosocial functioning. Scores range from 0-100 with higher values representing higher functioning and better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":"9.77"},{"groupId":"OG001","value":"65.2","spread":"9.83"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":[]}}}